Patent ID: 8026244

Claim:
A compound of Formula (I) or a pharmaceutically acceptable salt thereof: wherein at least one of X and Y is S, and the other is O or S; L is ethylene, methylene, —CH 2 CH(CH 3 )OCH 2 —, —CH 2 CH(C 6 H 5 )—, —CH 2 CH 2 NHCH 2 —, —CH 2 CH 2 N(CH 3 )CH 2 —, —CH 2 CH(CH 3 )NHCH 2 —, or —CH 2 CH(CH 3 )NHC(O)—; R 1 selected from indole, isoindole, benzimidazole, quinoline, naphthyridine, imidazo[1,2-a]pyridine, pyrazole, pyrazine, oxadiazole, pyridine, isoxazole, pyrimidine, pyrrole, imidazole, furazan and triazole; wherein each R 1 is independently and optionally substituted with one or more substituents independently selected from halogen, CHF 2 , CH 2 F, CF 3 , SO (n) R 9 , SO (n) NR 9 R 10 , (CH 2 ) n R 3 , NR 4 R 5 , OH, C1 to 7 alkyl, C1 to 7 alkoxy, phenoxy, aryl, CN, C(O)NR 2 R 3 , NR 2 C(O)R 3 , C(O)R 3 , a 5- or 6-membered saturated or partially saturated ring containing one or more atoms selected from C, N, O, and S, and a mono- or bicyclic heteroaromatic ring system containing one or more heteroatoms selected from N, S, and O; and wherein said C1 to 7 alkoxy is optionally substituted with C1 to 6 alkoxy or aryl; wherein said C1 to 7 alkyl is optionally substituted with hydroxy or C1 to 6 alkoxy; wherein said C1 to 7 alkyl is optionally incorporating a carbonyl at any position in the C1 to 7 alkyl; and wherein said phenoxy is optionally substituted with C1 to 6 alkyl, halogen or C1 to 6 alkoxy; at each occurrence, R 2 , R 3 , R 4 , R 5 , R 9 and R 10 are independently selected from hydrogen, C1 to 6 alkyl, C1 to 6 alkoxy, aryl, and phenoxy; and said C1 to 6 alkyl is optionally substituted with halogen, C1 to 6 alkoxy, CHO, C2 to 6 alkanoyl, OH, C(O)NR 7 R 8 or NR 7 C(O)R 8 ; and said aryl or said phenoxy is optionally substituted with C1 to 6 alkyl, halogen or C1 to 6 alkoxy; or the groups NR 2 R 3 , NR 4 R 5 and NR 9 R 10 each independently represents a 5 to 7 membered saturated azacyclic ring optionally incorporating one additional heteroatom selected from O, S and NR 11 , said ring being optionally further substituted with halogen, C1 to 6 alkoxy, CHO, C2 to 6 alkanoyl, OH, C(O)NR 7 R 8 or NR 7 C(O)R 8 ; at each occurrence R 7 , R 8 and R 11 independently represent hydrogen or C1 to 6 alkyl, or the group NR 7 R 8 represents a 5 to 7 membered saturated azacyclic ring optionally incorporating one additional heteroatom selected from O, S, and NR 11 ; and n is 0, 1 or 2.